Evaluation of the prescription of osteoporosis treatment after a major osteoporotic fracture

Journal of Clinical Rheumatology

Volumn 20, Issue 6, 2014, Pages 347-348

  Bouvet, Anaïs ^a   Sabatier, Brigitte ^a   Savoldelli, Virginie ^a   Caruba, Thibaut ^a   Pouchot, Jacques ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; RALOXIFENE; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

AGED; FEMALE; FRAGILITY FRACTURE; HIP FRACTURE; HOME CARE; HUMAN; JAW OSTEONECROSIS; LETTER; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; REHABILITATION CENTER; RETROSPECTIVE STUDY; VITAMIN SUPPLEMENTATION; WRIST FRACTURE; COMPLICATION; DIET SUPPLEMENTATION; EVALUATION STUDY; FOLLOW UP; FRACTURES, BONE; FRANCE; HIP FRACTURES; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY; WRIST INJURIES;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CALCIUM; DIETARY SUPPLEMENTS; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; FRANCE; HIP FRACTURES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PRESCRIPTIONS; RALOXIFENE; RETROSPECTIVE STUDIES; THIOPHENES; TREATMENT OUTCOME; VITAMIN D; WRIST INJURIES;

EID: 84906768860     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0000000000000154     Document Type: Letter

References (11)

1. Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367:2010-2018.
2. Mehrpour SR, Aghamirsalim MR, Sorbi R. Are hospitalized patients with fragile fractures managed properly in relation to underlying osteoporosis? J Clin Rheumatol. 2012;18: 122-124.
3. Giangregorio L, Papaioannou A, Cranney A, et al. Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum. 2006;35:293-305.
4. Gehlbach SH, Avrunin JS, Puleo E, et al. Fracture risk and antiresorptive medication use in older women in the USA. Osteoporosis Int. 2007;18:805-810.
5. Briot K, Cortet B, Thomas T, et al. 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine. 2012;79:304-313.
6. Blain H. New French recommendations for the treatment of post-menopausal osteoporosis. What are the implications for the general internists? [in French]. Rev Med Interne. 2014;35:1-3.
7. Baio G, Barbagallo M, D'Avola G, et al. Improving adherence in osteoporosis: a new management algorithm for the patient with osteoporosis. Expert Opin Pharmacother. 2011;12:257-268.
8. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799-1809.
9. Patel VP, Mathew R, Raptis D, et al. Overcoming barriers to secondary prevention in hip fracture patients: an electronic referral and management system for osteoporosis. Injury. 2010;41:1249-1255.
10. Levasseur R, Sabatier J-P, Guilcher C, et al. Medical management of patients over 50 years admitted to orthopedic surgery for low-energy fracture. Joint Bone Spine. 2007;74:160-165.
11. Malochet-Guinamand S, Chalard N, Billault C, et al. Osteoporosis treatment in postmenopausal women after peripheral fractures: impact of information to general practitioners. Joint Bone Spine. 2005;72:562-566.